Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both

Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and rais

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) wit

Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response r

Wells Fargo analyst Derek Archila maintains Pyxis Oncology (NASDAQ:PYXS) with a Overweight and ra

Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre

MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and

Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’

Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's aft

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutic

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.40) per share which missed the analyst

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul

Wall Street analysts changed outlook on top names. For full changes, see our analyst ratings page. A

Wells Fargo analyst Derek Archila initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Overw

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues

Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regu

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.37) per share which met the analyst co

Wedbush analyst Robert Driscoll initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Outperf

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst c

RBC Capital analyst Leonid Timashev maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) wit

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO a

Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overwei

Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the p

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage compa

Guggenheim analyst Brad Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rati

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.30) per share which beat the analyst c

On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.'s

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater l

Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics

RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) wi

Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(1.32) per share which missed the analyst